Development of Therapeutics for Orthopoxvirus and Enterovirus infections: Small Molecule Antiviral Drug Discovery and Library Generation

Endemic diseases have the potential to spread quickly and overwhelm vulnerable populations, leading to the necessity for antiviral drugs to treat infections. This work focuses on the development of antivirals for orthopoxviruses and enteroviruses, as well as compound library development. Orthopoxviruses, which include monkeypox virus (mpox), vaccinia virus, and the eradicated smallpox virus, have few approved therapies, with no antiviral drug being approved for mpox infection. The viral p37 protein is a known therapeutic target for poxvirus antivirals. Tecovirimat is a known p37 inhibitor; however, it did not effectively treat mpox infections in clinical trials. Tecovirimat contains a large hydrocarbon motif, and previous changes in this motif have retained some antiviral efficacy. We identified a series of compounds containing amide, hydrazide, and carbamide linkers with adamantane, noradamantane, and other cyclic hydrocarbon substitutions with sub-micromolar potency targeting p37. The second focus of this work was the development of antivirals targeting Enterovirus-D68 (EV-D68). EV-D68 is an upper respiratory virus associated with polio-like acute flaccid myelitis (AFM) and primarily represents a threat to children under 16. Currently, there is no vaccine or Food and Drug Administration (FDA)-approved drug to combat EV-D68 infections. We used high-throughput screening to identify a promising hit molecule that we further optimized. We identified that the target was the VP1 capsid protein. We identified candidates Jun14135 and Jun14934 having broad-spectrum antiviral activity against multiple strains of EV-D68. Furthermore, we identified the potential for co-therapy opportunities of Jun16934 with the EV-D68 2C inhibitor Jun6504. Finally, we look to improve the speed of preclinical development for covalent inhibitors by developing a direct-to-biology (D2B) methodology to quickly synthesize molecules for screening. D2B is being increasingly utilized by both industry and academia, primarily due to the potential to save both time and cost by using small amounts of crude reactions for use in biological assays.

Authors

Publication Details

Journal
Rutgers University Community Repository (Rutgers University)
Published
2026-11-17
DOI
https://doi.org/10.7282/t3-mfq6-xt72
Primary Topic
Computational Drug Discovery Methods
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Development of Therapeutics for Orthopoxvirus and Enterovirus infections: Small Molecule Antiviral Drug Discovery and Library Generation

Ryan Joyce
3 links
Rutgers University Community Repository (Rutgers University)
Computational Drug Discovery Methods
article

Development of Therapeutics for Orthopoxvirus and Enterovirus infections: Small Molecule Antiviral Drug Discovery and Library Generation

Ryan Joyce
article en

Abstract

Endemic diseases have the potential to spread quickly and overwhelm vulnerable populations, leading to the necessity for antiviral drugs to treat infections. This work focuses on the development of antivirals for orthopoxviruses and enteroviruses, as well as compound library development. Orthopoxviruses, which include monkeypox virus (mpox), vaccinia virus, and the eradicated smallpox virus, have few approved therapies, with no antiviral drug being approved for mpox infection. The viral p37 protein is a known therapeutic target for poxvirus antivirals. Tecovirimat is a known p37 inhibitor; however, it did not effectively treat mpox infections in clinical trials. Tecovirimat contains a large hydrocarbon motif, and previous changes in this motif have retained some antiviral efficacy. We identified a series of compounds containing amide, hydrazide, and carbamide linkers with adamantane, noradamantane, and other cyclic hydrocarbon substitutions with sub-micromolar potency targeting p37. The second focus of this work was the development of antivirals targeting Enterovirus-D68 (EV-D68). EV-D68 is an upper respiratory virus associated with polio-like acute flaccid myelitis (AFM) and primarily represents a threat to children under 16. Currently, there is no vaccine or Food and Drug Administration (FDA)-approved drug to combat EV-D68 infections. We used high-throughput screening to identify a promising hit molecule that we further optimized. We identified that the target was the VP1 capsid protein. We identified candidates Jun14135 and Jun14934 having broad-spectrum antiviral activity against multiple strains of EV-D68. Furthermore, we identified the potential for co-therapy opportunities of Jun16934 with the EV-D68 2C inhibitor Jun6504. Finally, we look to improve the speed of preclinical development for covalent inhibitors by developing a direct-to-biology (D2B) methodology to quickly synthesize molecules for screening. D2B is being increasingly utilized by both industry and academia, primarily due to the potential to save both time and cost by using small amounts of crude reactions for use in biological assays.

Rutgers University Community Repository (Rutgers University)
Good health and well-being
Computational Drug Discovery Methods
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon